Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 119

1.

Ovarian carcinoma glyco-antigen targeted by human IgM antibody.

Chen Y, Bieber MM, Bhat NM, Teng NNH.

PLoS One. 2017 Dec 21;12(12):e0187222. doi: 10.1371/journal.pone.0187222. eCollection 2017.

2.

Targeting FOXM1 Improves Cytotoxicity of Paclitaxel and Cisplatinum in Platinum-Resistant Ovarian Cancer.

Westhoff GL, Chen Y, Teng NNH.

Int J Gynecol Cancer. 2017 Oct;27(8):1602-1609. doi: 10.1097/IGC.0000000000001063.

PMID:
28692634
3.

Secondary Somatic Mutations Restoring RAD51C and RAD51D Associated with Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma.

Kondrashova O, Nguyen M, Shield-Artin K, Tinker AV, Teng NNH, Harrell MI, Kuiper MJ, Ho GY, Barker H, Jasin M, Prakash R, Kass EM, Sullivan MR, Brunette GJ, Bernstein KA, Coleman RL, Floquet A, Friedlander M, Kichenadasse G, O'Malley DM, Oza A, Sun J, Robillard L, Maloney L, Bowtell D, Giordano H, Wakefield MJ, Kaufmann SH, Simmons AD, Harding TC, Raponi M, McNeish IA, Swisher EM, Lin KK, Scott CL; AOCS Study Group.

Cancer Discov. 2017 Sep;7(9):984-998. doi: 10.1158/2159-8290.CD-17-0419. Epub 2017 Jun 6.

4.

Targeting Foxm1 Improves Cytotoxicity of Paclitaxel and Cisplatinum in Platinum-Resistant Ovarian Cancer.

Westhoff GL, Chen Y, Teng NNH.

Int J Gynecol Cancer. 2017 Jun;27(5):887-894. doi: 10.1097/IGC.0000000000000969.

PMID:
28498253
5.

Identification of Cell Surface Straight Chain Poly-N-Acetyl-Lactosamine Bearing Protein Ligands for VH4-34-Encoded Natural IgM Antibodies.

Bhat NM, Adams CM, Chen Y, Bieber MM, Teng NN.

J Immunol. 2015 Dec 1;195(11):5178-88. doi: 10.4049/jimmunol.1501697. Epub 2015 Oct 26.

6.

Differentiating between borderline and invasive malignancies in ovarian tumors using a multivariate logistic regression model.

Chen J, Chang C, Huang HC, Chung YC, Huang HJ, Liou WS, Chiang AJ, Teng NN.

Taiwan J Obstet Gynecol. 2015 Aug;54(4):398-402. doi: 10.1016/j.tjog.2014.02.004.

7.

In silico investigation of FOXM1 binding and novel inhibitors in epithelial ovarian cancer.

Chen Y, Ruben EA, Rajadas J, Teng NN.

Bioorg Med Chem. 2015 Aug 1;23(15):4576-82. doi: 10.1016/j.bmc.2015.06.002. Epub 2015 Jun 6.

PMID:
26164623
8.

IgG Subclasses and Isotypes of VH4-34 Encoded Antibodies.

Bhat NM, Kshirsagar MA, Bieber MM, Teng NN.

Immunol Invest. 2015;44(4):400-10. doi: 10.3109/08820139.2015.1015682.

PMID:
25942350
9.

Does omentectomy in epithelial ovarian cancer affect survival? An analysis of the Surveillance, Epidemiology, and End Results database.

McNally L, Teng NN, Kapp DS, Karam A.

Int J Gynecol Cancer. 2015 May;25(4):607-15. doi: 10.1097/IGC.0000000000000412.

PMID:
25756404
10.

Cell-penetrating, guanidinium-rich molecular transporters for overcoming efflux-mediated multidrug resistance.

Vargas JR, Stanzl EG, Teng NN, Wender PA.

Mol Pharm. 2014 Aug 4;11(8):2553-65. doi: 10.1021/mp500161z. Epub 2014 May 9. Review.

11.

The omentum and omentectomy in epithelial ovarian cancer: a reappraisal: part II--The role of omentectomy in the staging and treatment of apparent early stage epithelial ovarian cancer.

Arie AB, McNally L, Kapp DS, Teng NN.

Gynecol Oncol. 2013 Dec;131(3):784-90. doi: 10.1016/j.ygyno.2013.09.013. Epub 2013 Sep 18. Review.

PMID:
24056005
12.

The omentum and omentectomy in epithelial ovarian cancer: a reappraisal. Part I--Omental function and history of omentectomy.

Ben Arie A, McNally L, Kapp DS, Teng NN.

Gynecol Oncol. 2013 Dec;131(3):780-3. doi: 10.1016/j.ygyno.2013.09.014. Epub 2013 Sep 18. Review.

PMID:
24056004
13.

Impact of navigation on knowledge and attitudes about clinical trials among Chinese patients undergoing treatment for breast and gynecologic cancers.

Clair McClung E, Davis SW, Jeffrey SS, Kuo MC, Lee MM, Teng NN.

J Immigr Minor Health. 2015 Jun;17(3):976-9. doi: 10.1007/s10903-013-9901-x.

PMID:
23963874
14.

Hedgehog signaling regulates drug sensitivity by targeting ABC transporters ABCB1 and ABCG2 in epithelial ovarian cancer.

Chen Y, Bieber MM, Teng NN.

Mol Carcinog. 2014 Aug;53(8):625-34. doi: 10.1002/mc.22015. Epub 2013 Feb 19.

PMID:
23423781
15.

Taxol-oligoarginine conjugates overcome drug resistance in-vitro in human ovarian carcinoma.

Wender PA, Galliher WC, Bhat NM, Pillow TH, Bieber MM, Teng NN.

Gynecol Oncol. 2012 Jul;126(1):118-23. doi: 10.1016/j.ygyno.2012.03.049. Epub 2012 Apr 6.

16.

The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors.

Willingham SB, Volkmer JP, Gentles AJ, Sahoo D, Dalerba P, Mitra SS, Wang J, Contreras-Trujillo H, Martin R, Cohen JD, Lovelace P, Scheeren FA, Chao MP, Weiskopf K, Tang C, Volkmer AK, Naik TJ, Storm TA, Mosley AR, Edris B, Schmid SM, Sun CK, Chua MS, Murillo O, Rajendran P, Cha AC, Chin RK, Kim D, Adorno M, Raveh T, Tseng D, Jaiswal S, Enger PØ, Steinberg GK, Li G, So SK, Majeti R, Harsh GR, van de Rijn M, Teng NN, Sunwoo JB, Alizadeh AA, Clarke MF, Weissman IL.

Proc Natl Acad Sci U S A. 2012 Apr 24;109(17):6662-7. doi: 10.1073/pnas.1121623109. Epub 2012 Mar 26.

17.

Prox-1, Podoplanin and HPV staining assists in identification of lymphangioma circumscriptum of the vulva and discrimination from vulvar warts.

Sultan A, Dadras SS, Bay JM, Teng NN.

Histopathology. 2011 Dec;59(6):1274-7. doi: 10.1111/j.1365-2559.2011.03994.x. Epub 2011 Oct 25. No abstract available.

PMID:
22026919
18.

Phase I trial of a novel human monoclonal antibody mAb216 in patients with relapsed or refractory B-cell acute lymphoblastic leukemia.

Liedtke M, Twist CJ, Medeiros BC, Gotlib JR, Berube C, Bieber MM, Bhat NM, Teng NN, Coutre SE.

Haematologica. 2012 Jan;97(1):30-7. doi: 10.3324/haematol.2011.045997. Epub 2011 Oct 11.

19.

Leukemia inhibitory factor downregulates human papillomavirus-16 oncogene expression and inhibits the proliferation of cervical carcinoma cells.

Bay JM, Patterson BK, Teng NN.

Infect Dis Obstet Gynecol. 2011;2011:463081. doi: 10.1155/2011/463081. Epub 2011 Jun 4.

20.

Wnt and hedgehog gene pathway expression in serous ovarian cancer.

Schmid S, Bieber M, Zhang F, Zhang M, He B, Jablons D, Teng NN.

Int J Gynecol Cancer. 2011 Aug;21(6):975-80. doi: 10.1097/IGC.0b013e31821caa6f.

21.

Squamous cell carcinoma arising from mature cystic teratoma of the ovary.

Chiang AJ, La V, Peng J, Yu KJ, Teng NN.

Int J Gynecol Cancer. 2011 Apr;21(3):466-74. doi: 10.1097/IGC.0b013e31820d3e5b.

PMID:
21430455
22.

Gynecologic malignancies in female-to-male transgender patients: the need of original gender surveillance.

Urban RR, Teng NN, Kapp DS.

Am J Obstet Gynecol. 2011 May;204(5):e9-e12. doi: 10.1016/j.ajog.2010.12.057. Epub 2011 Feb 26.

PMID:
21354550
23.

The incidence of isolated para-aortic nodal metastasis in completely staged endometrial cancer patients.

Chiang AJ, Yu KJ, Chao KC, Teng NN.

Gynecol Oncol. 2011 Apr;121(1):122-5. doi: 10.1016/j.ygyno.2010.11.026. Epub 2010 Dec 30.

PMID:
21194737
24.

Trends in demographic and clinical characteristics in women diagnosed with corpus cancer and their potential impact on the increasing number of deaths.

Ueda SM, Kapp DS, Cheung MK, Shin JY, Osann K, Husain A, Teng NN, Berek JS, Chan JK.

Am J Obstet Gynecol. 2008 Feb;198(2):218.e1-6. doi: 10.1016/j.ajog.2007.08.075.

PMID:
18226630
25.

Prognostic factors and risk of extrauterine metastases in 3867 women with grade 1 endometrioid corpus cancer.

Chan JK, Kapp DS, Cheung MK, Shin JY, Stieglitz D, Husain A, Teng NN, Berek JS, Osann K, Guo H.

Am J Obstet Gynecol. 2008 Feb;198(2):216.e1-5. doi: 10.1016/j.ajog.2007.08.028.

PMID:
18226629
26.

Ovarian clear cell carcinoma with papillary features: a potential mimic of serous tumor of low malignant potential.

Sangoi AR, Soslow RA, Teng NN, Longacre TA.

Am J Surg Pathol. 2008 Feb;32(2):269-74. doi: 10.1097/PAS.0b013e31814fa9b0.

PMID:
18223330
27.

A novel technique for the enrichment of primary ovarian cancer cells.

Chan JK, Hamilton CA, Anderson EM, Cheung MK, Baker J, Husain A, Teng NN, Kong CS, Negrin RS.

Am J Obstet Gynecol. 2007 Nov;197(5):507.e1-5.

PMID:
17980191
28.

Influence of the gynecologic oncologist on the survival of ovarian cancer patients.

Chan JK, Kapp DS, Shin JY, Husain A, Teng NN, Berek JS, Osann K, Leiserowitz GS, Cress RD, O'Malley C.

Obstet Gynecol. 2007 Jun;109(6):1342-50.

PMID:
17540806
29.

The potential therapeutic role of lymph node resection in epithelial ovarian cancer: a study of 13918 patients.

Chan JK, Urban R, Hu JM, Shin JY, Husain A, Teng NN, Berek JS, Osann K, Kapp DS.

Br J Cancer. 2007 Jun 18;96(12):1817-22. Epub 2007 May 22.

30.

Lymphadenectomy in endometrioid uterine cancer staging: how many lymph nodes are enough? A study of 11,443 patients.

Chan JK, Urban R, Cheung MK, Shin JY, Husain A, Teng NN, Berek JS, Walker JL, Kapp DS, Osann K.

Cancer. 2007 Jun 15;109(12):2454-60.

31.

Acute postoperative thrombotic thrombocytopenic purpura following hysterectomy and lymphadenectomy for endometrial cancer.

Hamilton CA, Kao JM, Coutre SE, Teng NN.

Gynecol Oncol. 2007 Aug;106(2):423-6. Epub 2007 May 17.

PMID:
17499845
32.

Prognostic factors for uterine cancer in reproductive-aged women.

Lee NK, Cheung MK, Shin JY, Husain A, Teng NN, Berek JS, Kapp DS, Osann K, Chan JK.

Obstet Gynecol. 2007 Mar;109(3):655-62.

PMID:
17329517
33.

Safety and efficacy of lenalidomide (Revlimid) in recurrent ovarian and primary peritoneal carcinoma.

Zhang MM, Chan JK, Husain A, Guo HY, Teng NN.

Gynecol Oncol. 2007 Apr;105(1):194-8. Epub 2007 Jan 24.

PMID:
17257661
34.

Association of lymphadenectomy and survival in stage I ovarian cancer patients.

Chan JK, Munro EG, Cheung MK, Husain A, Teng NN, Berek JS, Osann K.

Obstet Gynecol. 2007 Jan;109(1):12-9.

PMID:
17197582
35.

Ovarian cancer in younger vs older women: a population-based analysis.

Chan JK, Urban R, Cheung MK, Osann K, Shin JY, Husain A, Teng NN, Kapp DS, Berek JS, Leiserowitz GS.

Br J Cancer. 2006 Nov 20;95(10):1314-20. Epub 2006 Oct 31. Erratum in: Br J Cancer. 2007 Feb 12;96(3):534. Shin, J Y [added]. Br J Cancer. 2007 May 7;96(9):1492.

36.

Prognostic factors responsible for survival in sex cord stromal tumors of the ovary--an analysis of 376 women.

Zhang M, Cheung MK, Shin JY, Kapp DS, Husain A, Teng NN, Berek JS, Osann K, Chan JK.

Gynecol Oncol. 2007 Feb;104(2):396-400. Epub 2006 Oct 9.

PMID:
17030354
37.

Mesonephric adenocarcinoma of the cervix: a case report and review of the literature.

Yap OW, Hendrickson MR, Teng NN, Kapp DS.

Gynecol Oncol. 2006 Dec;103(3):1155-8. Epub 2006 Oct 4. Review.

PMID:
17023031
38.

Therapeutic role of lymph node resection in endometrioid corpus cancer: a study of 12,333 patients.

Chan JK, Cheung MK, Huh WK, Osann K, Husain A, Teng NN, Kapp DS.

Cancer. 2006 Oct 15;107(8):1823-30.

39.

Patterns and progress in ovarian cancer over 14 years.

Chan JK, Cheung MK, Husain A, Teng NN, West D, Whittemore AS, Berek JS, Osann K.

Obstet Gynecol. 2006 Sep;108(3 Pt 1):521-8.

PMID:
16946210
40.

The benefit of adjuvant radiation therapy in single-node-positive squamous cell vulvar carcinoma.

Parthasarathy A, Cheung MK, Osann K, Husain A, Teng NN, Berek JS, Kapp DS, Chan JK.

Gynecol Oncol. 2006 Dec;103(3):1095-9. Epub 2006 Aug 4.

PMID:
16889821
41.

Safety and efficacy of thalidomide in recurrent epithelial ovarian and peritoneal carcinoma.

Chan JK, Manuel MR, Ciaravino G, Cheung MK, Husain A, Teng NN.

Gynecol Oncol. 2006 Dec;103(3):919-23. Epub 2006 Jul 7.

PMID:
16828852
42.

The effect of adjuvant chemotherapy versus whole abdominopelvic radiation on the survival of patients with advanced stage uterine papillary serous carcinoma.

Hamilton CA, Cheung MK, Osann K, Balzer B, Berman ML, Husain A, Teng NN, Kapp DS, Chan JK.

Gynecol Oncol. 2006 Nov;103(2):679-83. Epub 2006 Jun 21.

PMID:
16793126
43.

Outcomes of women with metachronous breast and ovarian carcinomas.

Liou WS, Hamilton CA, Cheung MK, Osann K, Longacre TA, Teng NN, Husain A, Dirbas FM, Chan JK.

Gynecol Oncol. 2006 Oct;103(1):190-4. Epub 2006 Mar 29.

PMID:
16569424
44.

Enhanced killing of primary ovarian cancer by retargeting autologous cytokine-induced killer cells with bispecific antibodies: a preclinical study.

Chan JK, Hamilton CA, Cheung MK, Karimi M, Baker J, Gall JM, Schulz S, Thorne SH, Teng NN, Contag CH, Lum LG, Negrin RS.

Clin Cancer Res. 2006 Mar 15;12(6):1859-67.

45.

Uterine papillary serous and clear cell carcinomas predict for poorer survival compared to grade 3 endometrioid corpus cancers.

Hamilton CA, Cheung MK, Osann K, Chen L, Teng NN, Longacre TA, Powell MA, Hendrickson MR, Kapp DS, Chan JK.

Br J Cancer. 2006 Mar 13;94(5):642-6.

46.

Breast cancer followed by corpus cancer: is there a higher risk for aggressive histologic subtypes?

Chan JK, Manuel MR, Cheung MK, Osann K, Husain A, Teng NN, Rao A, Carlson RW, Whittemore AS.

Gynecol Oncol. 2006 Sep;102(3):508-12. Epub 2006 Feb 17.

PMID:
16483640
47.

Improved survival of Asians with corpus cancer compared with whites: an analysis of underlying factors.

Zhang MM, Cheung MK, Osann K, Lee MM, Gomez SS, Whittemore AS, Husain A, Teng NN, Chan JK.

Obstet Gynecol. 2006 Feb;107(2 Pt 1):329-35.

PMID:
16449120
48.

Effects of human monoclonal antibody 216 on B-progenitor acute lymphoblastic leukemia in vitro.

Bieber MM, Twist CJ, Bhat NM, Teng NN.

Pediatr Blood Cancer. 2007 Apr;48(4):380-6.

PMID:
16421902
49.

Impact of adjuvant therapy on survival of patients with early-stage uterine papillary serous carcinoma.

Hamilton CA, Liou WS, Osann K, Berman ML, Husain A, Teng NN, Kapp DS, Chan JK.

Int J Radiat Oncol Biol Phys. 2005 Nov 1;63(3):839-44.

PMID:
16199314
50.

Intraoperative radiation therapy in recurrent ovarian cancer.

Yap OW, Kapp DS, Teng NN, Husain A.

Int J Radiat Oncol Biol Phys. 2005 Nov 15;63(4):1114-21. Epub 2005 Jun 20.

PMID:
15964710

Supplemental Content

Support Center